Evidence for distinct effects of GH and IGF-I in the metabolic syndrome

Diabetic Medicine

Volumn 24, Issue 9, 2007, Pages 1012-1018

  Maison, P ^a,e   Balkau, B ^b   Souberbielle, J C ^c   Cunin, P ^a   Vol, S ^d,i   Macquin Mavier, I ^a   Eschwege E ^b   Ducimetiere P ^b   Alhenc Gelas, F ^b   Gallois, Y ^f   Girault, A ^f   Fumeron, F ^g   Marre, M ^g   Cogneau, J ^h   Born, C ⁱ   Caces E ⁱ   Cailleau, M ⁱ   Moreau, J G ⁱ   Rakotozafy, F ⁱ   Tichet, J ⁱ  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b INSERM   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d IRSA   (France)

^e HENRI MONDOR HOSPITAL   (France)

^f ANGERS UNIVERSITY HOSPITAL   (France)

^g BICHAT HOSPITAL   (France)

^h Institut de Recherche en Médecine Générale

ⁱ Institut Régional pour la Santé

Author keywords

Diabetes; Growth hormone; Insulin growth factor I; Metabolic syndrome; Somatotropic axis

Indexed keywords

GLUCOSE; GROWTH HORMONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; SOMATOMEDIN C; TRIACYLGLYCEROL;

ADULT; ANALYTICAL PARAMETERS; ARTICLE; BLOOD PRESSURE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; EPIDEMIOLOGICAL DATA; FACTORIAL ANALYSIS; FEMALE; GLUCOSE BLOOD LEVEL; GROWTH HORMONE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; SEX DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL; VARIANCE; WAIST CIRCUMFERENCE;

ADULT; BLOOD GLUCOSE; BODY COMPOSITION; DIABETES MELLITUS, TYPE 2; FEMALE; GROWTH HORMONE-RELEASING HORMONE; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; QUESTIONNAIRES; RISK FACTORS;

EID: 34548141859     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2007.02195.x     Document Type: Article

References (43)

1. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome - a new worldwide definition. Lancet 2005 366:1059 1062.
2. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001 24:683 689.
3. Tomlinson JW, Holden N, Hills RK, Wheatley K, Clayton RN, Bates AS et al. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 2001 357:425 431.
4. Cuneo RC, Salomon F, McGauley GA, Sonksen PH. The growth hormone deficiency syndrome in adults. Clin Endocrinol (Oxf) 1992 37:387 397.
5. Maison P, Griffin S, Nicoue-Beglah M, Haddad N, Balkau B, Chanson P. Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a Metaanalysis of Blinded, Randomized, Placebo-Controlled Trials. J Clin Endocrinol Metab 2004 89:2192 2199.
6. Sandhu MS, Heald AH, Gibson JM, Cruickshank JK, Dunger DB, Wareham NJ. Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study. Lancet 2002 359:1740 1745.
7. Juul A, Scheike T, Davidsen M, Gyllenborg J, Jorgensen T. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation 2002 106:939 944.
8. Sandhu MS, Gibson JM, Heald AH, Dunger DB, Wareham NJ. Low circulating IGF-II concentrations predict weight gain and obesity in humans. Diabetes 2003 52:1403 1408.
9. Kaushal K, Heald AH, Siddals KW, Sandhu MS, Dunger DB, Gibson JM et al. The impact of abnormalities in IGF and inflammatory systems on the metabolic syndrome. Diabetes Care 2004 27:2682 2688.
10. Franco C, Brandberg J, Lonn L, Andersson B, Bengtsson BA, Johannsson G. Growth hormone treatment reduces abdominal visceral fat in postmenopausal women with abdominal obesity: a 12-month placebo-controlled trial. J Clin Endocrinol Metab 2005 90:1466 1474.
11. Johannsson G, Marin P, Lonn L, Ottosson M, Stenlof K, Bjorntorp P et al. Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure. J Clin Endocrinol Metab 1997 82:727 734.
12. Johannsson G, Bengtsson BA. Growth hormone and the metabolic syndrome. J Endocrinol Invest 1999 22:41 46.
13. Mauras N, Haymond MW. Are the metabolic effects of GH and IGF-I separable? Growth Horm IGF Res 2005 15:19 27.
14. Anker SD, Volterrani M, Pflaum CD, Strasburger CJ, Osterziel KJ, Doehner W et al. Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone. J Am Coll Cardiol 2001 38:443 452.
15. Bouvier-Colle M, Jougla E, Schwoebel V. Une enquête épidémiologique réalisée à partir d'un réseau de centres d'examens de santé français (DESIR: Données Epidémiologiques sur le Syndrome d'Insulino-Resistance). Rev Epidem Santé Publ 1996 44:373 384.
16. Gallois Y, Vol S, Caces E, Balkau B. Distribution of fasting serum insulin measured by enzyme immunoassay in an unselected population of 4032 individuals. Reference values according to age and sex. D.E.S.I.R. Study Group. Donnees Epidemiologiques sur le Syndrome d'Insulino-Resistance. Diabetes Metab 1996 22:427 431.
17. The International Diabetes Federation (IDF). The IDF Consensus Worldwide Definition of the Metabolic Syndrome, Brussels edn. 2005. Available from: http://www.idf.org/webdata/docs/IDF_Metasyndrome_definition.pdf (accessed 23 April 2007).
18. Cattell RB. Factor analyis: an introduction to essentials. Ii. The role of factor analysis in research. Biometrics 1965 21:405 435.
19. Cuneo RC, Judd S, Wallace JD, Perry-Keene D, Burger H, Lim-Tio S et al. The Australian multicenter trial of growth hormone (GH) treatment in GH-deficient adults. J Clin Endocrinol Metab 1998 83:107 116.
20. Maison P, Byrne CD, Hales CN, Day NE, Wareham NJ. Do different dimensions of the metabolic syndrome change together over time? Evidence supporting obesity as the central feature. Diabetes Care 2001 24:1758 1763.
21. Ferrannini E, Haffner SM, Mitchell BD, Stern MP. Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia 1991 34:416 422.
22. Edwards KL, Austin MA, Newman B, Mayer E, Krauss RM, Selby JV. Multivariate analysis of the insulin resistance syndrome in women. Arterioscler Thromb 1994 14:1940 1945.
23. Edwards KL, Burchfiel CM, Sharp DS, Curb JD, Rodriguez BL, Fujimoto WY et al. Factors of the insulin resistance syndrome in non-diabetic and diabetic elderly Japanese-American men. Am J Epidemiol 1998 147:441 447.
24. Ezzat S, Fear S, Gaillard RC, Gayle C, Landy H, Marcovitz S et al. Gender-specific responses of lean body composition and non-gender-specific cardiac function improvement after GH replacement in GH-deficient adults. J Clin Endocrinol Metab 2002 87:2725 2733.
25. Bengtsson BA, Johannsson G. Effect of growth-hormone therapy on early atherosclerotic changes in GH-deficient adults. Lancet 1999 353:1898 1899.
26. Span JP, Pieters GF, Sweep CG, Hermus AR, Smals AG. Gender difference in insulin-like growth factor I response to growth hormone (GH) treatment in GH-deficient adults: role of sex hormone replacement. J Clin Endocrinol Metab 2000 85:1121 1125.
27. Thrailkill KM. Insulin-like growth factor-I in diabetes mellitus: its physiology, metabolic effects, and potential clinical utility. Diabetes Technol Ther 2000 2:69 80.
28. Frystyk J, Skjaerbaek C, Vestbo E, Fisker S, Orskov H. Circulating levels of free insulin-like growth factors in obese subjects: the impact of type 2 diabetes. Diabetes Metab Res Rev 1999 15:314 322.
29. Froesch ER, Bianda T, Hussain MA. Insulin-like growth factor-I in the therapy of non-insulin-dependent diabetes mellitus and insulin resistance. Diabetes Metab 1996 22:261 267.
30. Moses AC, Young SC, Morrow LA, O'Brien M, Clemmons DR. Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes. Diabetes 1996 45:91 100.
31. Foster CM, Hale PM, Jing HW, Schwartz J. Effects of human growth hormone on insulin-stimulated glucose metabolism in 3T3-F442A adipocytes. Endocrinology 1988 123:1082 1088.
32. Rudling M, Parini P, Angelin B. Growth hormone and bile acid synthesis. Key role for the activity of hepatic microsomal cholesterol 7α-hydroxylase in the rat. J Clin Invest 1997 99:2239 2245.
33. Fineberg SE, Merimee TJ. Acute metabolic effects of human growth hormone. Diabetes 1974 23:499 504.
34. Maison P, Griffin S, Nicoue-Beglah M, Haddad N, Balkau B, Chanson P. Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a Metaanalysis of Blinded, Randomized, Placebo-Controlled Trials. J Clin Endocrinol Metab 2004 89:2192 2199.
35. Yin D, Clarke SD, Etherton TD. Transcriptional regulation of fatty acid synthase gene by somatotropin in 3T3-F442A adipocytes. J Anim Sci 2001 79:2336 2345.
36. Nam SY, Lobie PE. The mechanism of effect of growth hormone on preadipocyte and adipocyte function. Obes Rev 2000 1:73 86.
37. Sacca L, Fazio S, Longobardi S, Cittadini A. Cardiac effects of growth hormone in physiology and in heart failure. Endocr J 1999 46:S5 10.
38. Ikkos D, Luft R, Sjogren B. Body water and sodium in patients with acromegaly. J Clin Invest 1954 33:989 994.
39. Muniyappa R, Walsh MF, Rangi JS, Zayas RM, Standley PR, Ram JL et al. Insulin like growth factor 1 increases vascular smooth muscle nitric oxide production. Life Sci 1997 61:925 931.
40. Sowers JR. Insulin and insulin-like growth factor in normal and pathological cardiovascular physiology. Hypertension 1997 29:691 699.
41. Jorgensen JO, Christensen JJ, Vestergaard E, Fisker S, Ovesen P, Christiansen JS. Sex steroids and the growth hormone/insulin-like growth factor-I axis in adults. Horm Res 2005 64:37 40.
42. Laughlin GA, Barrett-Connor E, Criqui MH, Kritz-Silverstein D. The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study. J Clin Endocrinol Metab 2004 89:114 120.
43. Maison P, Balkau B, Simon D, Chanson P, Rosselin G, Eschwege E. Growth hormone as a risk for premature mortality in healthy subjects: data from the Paris prospective study. Br Med J 1998 316:1132 1133.